ClinicalTrials.gg
CompletedNCT03331835Updated Mar 13, 2025Results posted

A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis

A Phase 4 interventional study of Brodalumab and Fumaric acid esters in Psoriasis Vulgaris, sponsored by LEO Pharma. Completed at 30 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-13.

Sponsored by LEO Pharma · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing brodalumab in Psoriasis — none open to participants now, 1 under way, none of them phase 3. brodalumab · Psoriasis.

Enrollment
6th of 26
210 · median 132
Started
2017
with 2 others
Phase 4
10 of 26
none open now
Registered
16th of 26
by date
Lead sponsor
4 of 26
LEO Pharma

Among the 26 studies testing brodalumab in Psoriasis, this one is the 6th largest by enrollment, is one of 3 that started in 2017, is one of 10 in phase 4, and was the 16th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

None of the 26 studies testing brodalumab in Psoriasis is open now. The open studies under Psoriasis, anywhere →

About brodalumab

brodalumab: first FDA approval 2017 (SILIQ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing brodalumab in Psoriasis as a file.
02

Study summary

The primary objective is to demonstrate added benefit of brodalumab versus a selected systemic comparator in treatment of moderate to severe plaque psoriasis in Germany in subjects who have not previously received systemic treatment for psoriasis.

Fumaric acid esters have been selected as the comparator because it is an established systemic treatment of psoriasis in Germany.

Read the detailed description

A 24-week, randomised, open-label, active-controlled, parallel group, multi-centre trial with investigator-blinded efficacy assessments

03

Conditions studied

  • Psoriasis Vulgaris

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Criteria for Inclusion:

  • Men or women ≥18 years of age at the time of screening.
  • Subjects with chronic plaque type psoriasis diagnosed at least 6 months before randomisation.
  • Subjects with moderate to severe plaque psoriasis in whom topical therapy is not adequate and who are candidates for systemic therapy, defined at randomisation by PASI 10, affected BSA >10%, and DLQI >10.
  • Subject has no known history of active tuberculosis.
  • Subject has a negative test for tuberculosis taken at screening (negative Quantiferon test).
  • Subject and/or subject's designee is/are capable of administering subcutaneous injections.

Main Criteria for Exclusion:

  • Previous or current systemic treatment of plaque psoriasis or known for systemic therapy.
  • Previous or current PUVA (psoralens and ultraviolet A) therapy.
  • Washouts and non-permitted drugs:

    1. Have received phototherapy (UVA light therapy without psoralens, UVB light therapy, excimer laser, tanning beds etc. within 4 weeks of baseline, or
    2. Have had topical psoriasis treatment within 2 weeks of baseline (exceptions: bland emollients without urea or beta or alpha hydroxy acids)
    3. Have received any biologic immune modulating treatments used for indication other than psoriasis within 4 weeks of baseline or within a period of 5 half-lives of the IMP, whichever is longer
    4. Have received any other systemic immune modulating treatment (including but not limited to oral retinoids, methotrexate, calcineurin inhibitors, oral or parenteral etc. used for indications other than psoriasis) within 4 weeks of baseline or within a period of 5 half-lives of the IMP, whichever is longer.
  • Subjects with any of the following laboratory abnormalities at screening:

    1. Leukocyte cell count below 3×10\^9/L or lymphocyte count below 0.7×10\^9/L
    2. (AST) or alanine transferase (ALT) > 2× (upper level of normal limit)
    3. \< 2×10\^9/L
    4. Serum creatinine > ULN.
  • History of depressive disorder within the last 2 years including current antidepressive treatment.
  • Subjects with a history of suicidal behaviour (suicide attempt).
  • Any suicidal ideation of severity 4 or 5 based on the eC-SSRS questionnaire at screening.
  • A PHQ-8 score of ≥10 corresponding to moderate to severe depression at screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
210 participants (actual)

Study arms

  • Experimental
    Brodalumab

    Kyntheum® (brodalumab) pre-filled syringe 210 mg/1.5 mL solution for subcutaneous injections. First 3 injections are administered weekly, and hereafter every two weeks (Q2W).

    Biological: Brodalumab

  • Active comparator
    Fumaric acid esters

    Fumaderm® initial dose tablets (30 mg dimethyl fumarate, 67 mg ethyl hydrogen fumarate calcium salt, 5 mg ethyl hydrogen fumarate magnesium salt, 3 mg ethyl hydrogen fumarate zinc salt) Fumaderm® tablets (120 mg dimethyl fumarate, 87 mg ethyl hydrogen fumarate calcium salt, 5 mg ethyl hydrogen fumarate magnesium salt, 3 mg ethyl hydrogen fumarate zinc salt) Fumaderm® tablets are administered orally up to 3 times daily in accordance with the dosing scheme in the label.

    Drug: Fumaric acid esters

Interventions

  • BiologicalBrodalumab

    Brodalumab is a recombinant fully human monoclonal immunoglobulin IgG2-antibody that binds with high affinity to human interleukin 17 receptor A (IL-17RA). Blocking IL-17RA inhibits IL-17 cytokine-induced responses and results in reduced or normalised inflammation of the skin in subjects with psoriasis.

    Also known as: Kyntheum®

  • DrugFumaric acid esters

    Fumaric acid esters have been used to treat psoriasis since 1959. Systemic therapy with fumaric acid esters is based on an established dosing scheme with a gradual increase to improve tolerability, especially with regards to gastrointestinal side effects.

    Also known as: Fumaderm®

06

What researchers measure

Primary outcomes

  1. Having Least 75% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 75 Response) From Baseline at Week 24

    The PASI score grades the extent and severity of psoriatic involvement for each of four body regions (head and neck, upper extremities, trunk, and lower extremities) using a 7-point scale for extent of involvement in each body region and 5-point scales for severity of each of the clinical signs redness, thickness, and scalliness in each body region. Psoriasis Area and Severity Index is a scale ranging from 0 (no disease) to 72 (maximal disease).

    Time frame: Baseline to Week 24

  2. Static Physician's Global Assessment (sPGA) Scale Score of 0 or 1 at Week 24

    sPGA is a 6-point scale that represents the average lesion severity on the trunk and limbs. The assessment is based on the condition of the disease at the time of evaluation. Static Physician's Global Assessment is a scale ranging rom 0 (clear skin) to 5 (severe disease).

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Having Least 90% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 90 Response) From Baseline at Week 24

    The PASI score grades the extent and severity of psoriatic involvement for each of four body regions (head and neck, upper extremities, trunk, and lower extremities) using a 7-point scale for extent of involvement in each body region and 5-point scales for severity of each of the clinical signs redness, thickness, and scalliness in each body region. Psoriasis Area and Severity Index is a scale ranging from 0 (no disease) to 72 (maximal disease).

    Time frame: Baseline to Week 24

  2. Having 100% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 100 Response) From Baseline at Week 24

    The PASI score grades the extent and severity of psoriatic involvement for each of four body regions (head and neck, upper extremities, trunk, and lower extremities) using a 7-point scale for extent of involvement in each body region and 5-point scales for severity of each of the clinical signs redness, thickness, and scalliness in each body region. Psoriasis Area and Severity Index is a scale ranging from 0 (no disease) to 72 (maximal disease).

    Time frame: Baseline to Week 24

  3. Change From Baseline at Week 24 in PASI Score

    The PASI score grades the extent and severity of psoriatic involvement for each of four body regions (head and neck, upper extremities, trunk, and lower extremities) using a 7-point scale for extent of involvement in each body region and 5-point scales for severity of each of the clinical signs redness, thickness, and scalliness in each body region. Psoriasis Area and Severity Index is a scale ranging from 0 (no disease) to 72 (maximal disease). A negative change in PASI score means that the PASI score was lower at the time of data collection.

    Time frame: Baseline to Week 24

  4. Percent Change From Baseline in PASI Score at Week 24

    The PASI score grades the extent and severity of psoriatic involvement for each of four body regions (head and neck, upper extremities, trunk, and lower extremities) using a 7-point scale for extent of involvement in each body region and 5-point scales for severity of each of the clinical signs redness, thickness, and scalliness in each body region. Psoriasis Area and Severity Index is a scale ranging from 0 (no disease) to 72 (maximal disease). A negative value in the percent change from baseline that the PASI score was lower at the time of data collection.

    Time frame: Baseline to Week 24

  5. Change From Baseline at Week 24 in Affected Body Surface Area (BSA)

    The surface area of the participant's hand (palm and fingers) is used as a reference measurement to calculate the percentage of each body region that is affected by psoriasis. One hand is approximately equal to 1% total BSA. Furthermore, the complete body surface area (BSA=100%) can be divided into regions that approximates percentages of BSA as follows: head and neck (10%), upper extremities (20%), the trunk including the axillae and groin (30%), and finally the lower extremities, including the buttocks (40%). A negative value in the percent change from baseline that the affected BSA was lower at the time of data collection.

    Time frame: Baseline to Week 24

  6. Psoriasis Symptom Inventory (PSI) Responder at Week 24 (Total Score ≤ 8, With no Item Scores > 1)

    The PSI consists of eight psoriasis-specific questions. Trial participants rated the severity of their symptoms in the last 24 hours from 'not at all' to 'very severe,' ranging from 0 to 4. Total scores range from 0 to 32 with higher scores indicating worse symptoms. PSI response is defined as total score ≤8 and no item score \>1. Symptom-free day is defined as having daily total PSI of 0 on that day.

    Time frame: Week 24

  7. PSI Total Score of 0 at Week 24

    The PSI consists of eight psoriasis-specific questions. Trial participants rated the severity of their symptoms in the last 24 hours from 'not at all' to 'very severe,' ranging from 0 to 4. Total scores range from 0 to 32 with higher scores indicating worse symptoms. PSI response is defined as total score ≤8 and no item score \>1. Symptom-free day is defined as having daily total PSI of 0 on that day.

    Time frame: Week 24

  8. Number of Symptom-free Days From Randomisation to Week 24

    The PSI consists of eight psoriasis-specific questions. Trial participants rated the severity of their symptoms in the last 24 hours from 'not at all' to 'very severe,' ranging from 0 to 4. Total scores range from 0 to 32 with higher scores indicating worse symptoms. PSI response is defined as total score ≤8 and no item score \>1. Symptom-free day is defined as having daily total PSI of 0 on that day.

    Time frame: Baseline to Week 24

  9. Burden of Symptoms

    Burden of symptoms was assessed as the normalised area under the curve (AUC) of PSI from baseline to the last available assessment. The AUC for the PSI total score was calculated for each participant using the standard trapezoidal rule. The AUC was normalised by dividing it with the time from baseline to the last available assessment of the PSI total score. The PSI consists of eight psoriasis-specific questions. Trial participants rated the severity of their symptoms in the last 24 hours from 'not at all' to 'very severe,' ranging from 0 to 4. Total scores range from 0 to 32 with higher scores indicating worse symptoms.

    Time frame: Baseline to Week 24

  10. Change From Baseline at Week 24 in Dermatology Life Quality Index (DLQI) Total Score

    DLQI consists of 10 items addressing the participant's perception of the impact of their skin disease on different aspects of their quality of life over the last week such as dermatology-related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment. Each item is scored on a 4 point Likert scale (0 = not at all ⁄not relevant; 1 = a little; 2 = a lot; 3 = very much). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor QoL.

    Time frame: Baseline to Week 24

  11. DLQI Total Score of 0 or 1 at Week 24

    DLQI consists of 10 items addressing the participant's perception of the impact of their skin disease on different aspects of their QoL over the last week such as dermatology-related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment. Each item is scored on a 4 point Likert scale (0 = not at all ⁄not relevant; 1 = a little; 2 = a lot; 3 = very much). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor QoL.

    Time frame: Week 24

Other outcomes

  1. Change From Baseline at Week 24 in NAPSI Total Score

    The Nail Psoriasis Severity Index (NAPSI) grades nails by first dividing the nail area with imaginary horizontal and vertical lines into 4 quarters. The following 8 clinical features of nail psoriasis are then scored based on the number of quarters in which the feature is present (0 to 4) to arrive at a NAPSI score of 0 to 32 for each nail: * Pitting. * Leukonychia. * Red spots in lunula. * Nail plate crumbling. * Oil drop (salmon patch) discoloration. * Onycholysis. * Nail bed hyperkeratosis. * Splinter haemorrhages. A negative change in NAPSI score means that the NAPSI score was lower at the time of data collection.

    Time frame: Baseline to Week 24

07

Results

Posted Feb 10, 2020
Limitations and caveats
Operational challenges with the ePRO diary device given to trial participants led to missing data at baseline and Week 24. This made the analyses of the secondary patient-reported endpoints PSI response rate and PSI total score of 0 or 1 impossible.

Participant flow

Participant flow — Overall Study
MilestoneBrodalumabFumaric Acid Esters
Started105105
Completed9158
Not completed1447

Outcome measures

PrimaryHaving Least 75% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 75 Response) From Baseline at Week 24

The PASI score grades the extent and severity of psoriatic involvement for each of four body regions (head and neck, upper extremities, trunk, and lower extremities) using a 7-point scale for extent of involvement in each body region and 5-point scales for severity of each of the clinical signs redness, thickness, and scalliness in each body region. Psoriasis Area and Severity Index is a scale ranging from 0 (no disease) to 72 (maximal disease).

Time frame:
Baseline to Week 24
Reported as:
Count of participants · Participants
Having Least 75% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 75 Response) From Baseline at Week 24
ParticipantsBrodalumabFumaric Acid Esters
Having Least 75% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 75 Response) From Baseline at Week 248540
Statistical analysis
  • Brodalumab vs Fumaric Acid Esters · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 42.86 · 95% CI 30.93 to 54.7995% CI and p-value are derived from CMH analysis stratified by weight group at baseline (≤100 kg, \> 100 kg).
PrimaryStatic Physician's Global Assessment (sPGA) Scale Score of 0 or 1 at Week 24

sPGA is a 6-point scale that represents the average lesion severity on the trunk and limbs. The assessment is based on the condition of the disease at the time of evaluation. Static Physician's Global Assessment is a scale ranging rom 0 (clear skin) to 5 (severe disease).

Time frame:
Baseline to Week 24
Reported as:
Count of participants · Participants
Static Physician's Global Assessment (sPGA) Scale Score of 0 or 1 at Week 24
ParticipantsBrodalumabFumaric Acid Esters
Static Physician's Global Assessment (sPGA) Scale Score of 0 or 1 at Week 246821
Statistical analysis
  • Brodalumab vs Fumaric Acid Esters · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 44.76 · 95% CI 32.81 to 56.7195% CI and p-value are derived from CMH analysis stratified by weight group at baseline (≤100 kg, \> 100 kg)
SecondaryHaving Least 90% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 90 Response) From Baseline at Week 24

The PASI score grades the extent and severity of psoriatic involvement for each of four body regions (head and neck, upper extremities, trunk, and lower extremities) using a 7-point scale for extent of involvement in each body region and 5-point scales for severity of each of the clinical signs redness, thickness, and scalliness in each body region. Psoriasis Area and Severity Index is a scale ranging from 0 (no disease) to 72 (maximal disease).

Time frame:
Baseline to Week 24
Reported as:
Count of participants · Participants
Having Least 90% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 90 Response) From Baseline at Week 24
ParticipantsBrodalumabFumaric Acid Esters
Having Least 90% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 90 Response) From Baseline at Week 246923
Statistical analysis
  • Brodalumab vs Fumaric Acid Esters · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 43.81 · 95% CI 31.78 to 55.84
SecondaryHaving 100% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 100 Response) From Baseline at Week 24

The PASI score grades the extent and severity of psoriatic involvement for each of four body regions (head and neck, upper extremities, trunk, and lower extremities) using a 7-point scale for extent of involvement in each body region and 5-point scales for severity of each of the clinical signs redness, thickness, and scalliness in each body region. Psoriasis Area and Severity Index is a scale ranging from 0 (no disease) to 72 (maximal disease).

Time frame:
Baseline to Week 24
Reported as:
Count of participants · Participants
Having 100% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 100 Response) From Baseline at Week 24
ParticipantsBrodalumabFumaric Acid Esters
Having 100% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 100 Response) From Baseline at Week 24429
Statistical analysis
  • Brodalumab vs Fumaric Acid Esters · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 31.43 · 95% CI 20.76 to 42.10
SecondaryChange From Baseline at Week 24 in PASI Score

The PASI score grades the extent and severity of psoriatic involvement for each of four body regions (head and neck, upper extremities, trunk, and lower extremities) using a 7-point scale for extent of involvement in each body region and 5-point scales for severity of each of the clinical signs redness, thickness, and scalliness in each body region. Psoriasis Area and Severity Index is a scale ranging from 0 (no disease) to 72 (maximal disease). A negative change in PASI score means that the PASI score was lower at the time of data collection.

Time frame:
Baseline to Week 24
Reported as:
Mean · score on a scale
Change From Baseline at Week 24 in PASI Score
score on a scaleBrodalumabFumaric Acid Esters
Change From Baseline at Week 24 in PASI Score-15.69 ± 0.59-12.62 ± 0.67
Statistical analysis
  • Brodalumab vs Fumaric Acid Esters · Mixed Models Analysis · p = <0.001 · Mean difference (net): -3.08 · 95% CI -4.83 to -1.33
SecondaryPercent Change From Baseline in PASI Score at Week 24

The PASI score grades the extent and severity of psoriatic involvement for each of four body regions (head and neck, upper extremities, trunk, and lower extremities) using a 7-point scale for extent of involvement in each body region and 5-point scales for severity of each of the clinical signs redness, thickness, and scalliness in each body region. Psoriasis Area and Severity Index is a scale ranging from 0 (no disease) to 72 (maximal disease). A negative value in the percent change from baseline that the PASI score was lower at the time of data collection.

Time frame:
Baseline to Week 24
Reported as:
Mean · percent change in PASI
Percent Change From Baseline in PASI Score at Week 24
percent change in PASIBrodalumabFumaric Acid Esters
Percent Change From Baseline in PASI Score at Week 24-90.03 ± 2.25-73.67 ± 2.63
Statistical analysis
  • Brodalumab vs Fumaric Acid Esters · Mixed Models Analysis · p = <0.001 · Mean difference (net): -16.36 · 95% CI -23.03 to -9.68
SecondaryChange From Baseline at Week 24 in Affected Body Surface Area (BSA)

The surface area of the participant's hand (palm and fingers) is used as a reference measurement to calculate the percentage of each body region that is affected by psoriasis. One hand is approximately equal to 1% total BSA. Furthermore, the complete body surface area (BSA=100%) can be divided into regions that approximates percentages of BSA as follows: head and neck (10%), upper extremities (20%), the trunk including the axillae and groin (30%), and finally the lower extremities, including the buttocks (40%). A negative value in the percent change from baseline that the affected BSA was lower at the time of data collection.

Time frame:
Baseline to Week 24
Reported as:
Mean · percent change
Change From Baseline at Week 24 in Affected Body Surface Area (BSA)
percent changeBrodalumabFumaric Acid Esters
Change From Baseline at Week 24 in Affected Body Surface Area (BSA)-20.82 ± 1.48-11.91 ± 1.48
Statistical analysis
  • Brodalumab vs Fumaric Acid Esters · Mixed Models Analysis · p = <0.001 · Mean difference (net): -8.91 · 95% CI -13.00 to -4.81
SecondaryPsoriasis Symptom Inventory (PSI) Responder at Week 24 (Total Score ≤ 8, With no Item Scores > 1)

The PSI consists of eight psoriasis-specific questions. Trial participants rated the severity of their symptoms in the last 24 hours from 'not at all' to 'very severe,' ranging from 0 to 4. Total scores range from 0 to 32 with higher scores indicating worse symptoms. PSI response is defined as total score ≤8 and no item score \>1. Symptom-free day is defined as having daily total PSI of 0 on that day.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Psoriasis Symptom Inventory (PSI) Responder at Week 24 (Total Score ≤ 8, With no Item Scores > 1)
ParticipantsBrodalumabFumaric Acid Esters
Psoriasis Symptom Inventory (PSI) Responder at Week 24 (Total Score ≤ 8, With no Item Scores > 1)1513
SecondaryPSI Total Score of 0 at Week 24

The PSI consists of eight psoriasis-specific questions. Trial participants rated the severity of their symptoms in the last 24 hours from 'not at all' to 'very severe,' ranging from 0 to 4. Total scores range from 0 to 32 with higher scores indicating worse symptoms. PSI response is defined as total score ≤8 and no item score \>1. Symptom-free day is defined as having daily total PSI of 0 on that day.

Time frame:
Week 24
Reported as:
Count of participants · Participants
PSI Total Score of 0 at Week 24
ParticipantsBrodalumabFumaric Acid Esters
PSI Total Score of 0 at Week 2453
SecondaryNumber of Symptom-free Days From Randomisation to Week 24

The PSI consists of eight psoriasis-specific questions. Trial participants rated the severity of their symptoms in the last 24 hours from 'not at all' to 'very severe,' ranging from 0 to 4. Total scores range from 0 to 32 with higher scores indicating worse symptoms. PSI response is defined as total score ≤8 and no item score \>1. Symptom-free day is defined as having daily total PSI of 0 on that day.

Time frame:
Baseline to Week 24
Reported as:
Mean · days
Number of Symptom-free Days From Randomisation to Week 24
daysBrodalumabFumaric Acid Esters
Number of Symptom-free Days From Randomisation to Week 240.44 ± 0.80.42 ± 1.3
SecondaryBurden of Symptoms

Burden of symptoms was assessed as the normalised area under the curve (AUC) of PSI from baseline to the last available assessment. The AUC for the PSI total score was calculated for each participant using the standard trapezoidal rule. The AUC was normalised by dividing it with the time from baseline to the last available assessment of the PSI total score. The PSI consists of eight psoriasis-specific questions. Trial participants rated the severity of their symptoms in the last 24 hours from 'not at all' to 'very severe,' ranging from 0 to 4. Total scores range from 0 to 32 with higher scores indicating worse symptoms.

Time frame:
Baseline to Week 24
Reported as:
Mean · score on a scale
Burden of Symptoms
score on a scaleBrodalumabFumaric Acid Esters
Burden of Symptoms6.00 ± 0.5410.92 ± 0.55
Statistical analysis
  • Brodalumab vs Fumaric Acid Esters · ANCOVA · p = <0.001 · Mean difference (final values): -4.92 · 95% CI -6.31 to -3.53
SecondaryChange From Baseline at Week 24 in Dermatology Life Quality Index (DLQI) Total Score

DLQI consists of 10 items addressing the participant's perception of the impact of their skin disease on different aspects of their quality of life over the last week such as dermatology-related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment. Each item is scored on a 4 point Likert scale (0 = not at all ⁄not relevant; 1 = a little; 2 = a lot; 3 = very much). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor QoL.

Time frame:
Baseline to Week 24
Reported as:
Mean · score on a scale
Change From Baseline at Week 24 in Dermatology Life Quality Index (DLQI) Total Score
score on a scaleBrodalumabFumaric Acid Esters
Change From Baseline at Week 24 in Dermatology Life Quality Index (DLQI) Total Score-16.67 ± 0.61-14.10 ± 0.70
Statistical analysis
  • Brodalumab vs Fumaric Acid Esters · Mixed Models Analysis · p = 0.004 · Mean difference (net): -2.57 · 95% CI -4.32 to -0.82
SecondaryDLQI Total Score of 0 or 1 at Week 24

DLQI consists of 10 items addressing the participant's perception of the impact of their skin disease on different aspects of their QoL over the last week such as dermatology-related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment. Each item is scored on a 4 point Likert scale (0 = not at all ⁄not relevant; 1 = a little; 2 = a lot; 3 = very much). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor QoL.

Time frame:
Week 24
Reported as:
Count of participants · Participants
DLQI Total Score of 0 or 1 at Week 24
ParticipantsBrodalumabFumaric Acid Esters
DLQI Total Score of 0 or 1 at Week 247027
Statistical analysis
  • Brodalumab vs Fumaric Acid Esters · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 40.95 · 95% CI 28.75 to 53.16
Other pre-specifiedChange From Baseline at Week 24 in NAPSI Total Score

The Nail Psoriasis Severity Index (NAPSI) grades nails by first dividing the nail area with imaginary horizontal and vertical lines into 4 quarters. The following 8 clinical features of nail psoriasis are then scored based on the number of quarters in which the feature is present (0 to 4) to arrive at a NAPSI score of 0 to 32 for each nail: * Pitting. * Leukonychia. * Red spots in lunula. * Nail plate crumbling. * Oil drop (salmon patch) discoloration. * Onycholysis. * Nail bed hyperkeratosis. * Splinter haemorrhages. A negative change in NAPSI score means that the NAPSI score was lower at the time of data collection.

Time frame:
Baseline to Week 24
Reported as:
Mean · score on a scale
Change From Baseline at Week 24 in NAPSI Total Score
score on a scaleBrodalumabFumaric Acid Esters
Change From Baseline at Week 24 in NAPSI Total Score-2.97 ± 0.54-1.26 ± 0.57
Statistical analysis
  • Brodalumab vs Fumaric Acid Esters · Mixed Models Analysis · p = 0.028 · Mean difference (net): -1.72 · 95% CI -3.24 to -0.19

Adverse events

Collected over From the first day of investigational medicinal product (IMP) administration and until 32 weeks later for brodalumab and 26 weeks later for fumaric acid esters. The difference in collection periods was due to the different half-lives of the IMPs.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brodalumab 210 mg0/104 (0%)3/104 (2.9%)66/104 (63.5%)
Fumaric Acid Ester0/102 (0%)1/102 (1%)90/102 (88.2%)
Most frequent serious events
Most frequent serious events
EventBrodalumab 210 mgFumaric Acid Ester
Crohn's diseaseGastrointestinal disorders0/1041/102
Reactive gastropathyGastrointestinal disorders1/1040/102
Pancreatic carcinoma metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1040/102
Stasis dermatitisSkin and subcutaneous tissue disorders1/1040/102
Most frequent other events
Showing 10 of 15
Most frequent other events
EventBrodalumab 210 mgFumaric Acid Ester
DiarrhoeaGastrointestinal disorders4/10459/102
Viral upper respiratory tract infectionInfections and infestations35/10421/102
FlushingVascular disorders0/10429/102
Abdominal pain upperGastrointestinal disorders2/10428/102
LymphopeniaBlood and lymphatic system disorders2/10414/102
HeadacheNervous system disorders13/10412/102
Abdominal painGastrointestinal disorders2/10411/102
NauseaGastrointestinal disorders6/1049/102
ArthralgiaMusculoskeletal and connective tissue disorders9/1044/102
OverdoseInjury, poisoning and procedural complications8/1040/102

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)BrodalumabFumaric Acid EstersTotal
<=18 years000
Between 18 and 65 years9697193
>=65 years9817
Sex: Female, Male
Sex: Female, Male(Participants)BrodalumabFumaric Acid EstersTotal
Female323365
Male7372145
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BrodalumabFumaric Acid EstersTotal
Hispanic or Latino000
Not Hispanic or Latino100103203
Unknown or Not Reported527
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BrodalumabFumaric Acid EstersTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American000
White104105209
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)BrodalumabFumaric Acid EstersTotal
Germany105105210
Height
Height(cm)BrodalumabFumaric Acid EstersTotal
Mean175 ± 9.6176 ± 9.8175 ± 9.7
Weight
Weight(kg)BrodalumabFumaric Acid EstersTotal
Mean87.8 ± 20.486.6 ± 21.187.2 ± 20.7
Mean weight in participants weighing <100 kg
Mean weight in participants weighing <100 kg(kg)BrodalumabFumaric Acid EstersTotal
Mean78.4 ± 11.977.2 ± 12.877.8 ± 12.4

9 further baseline measures are reported on the registry.

08

Study locations

30 sites
  • Fachklinik Bad Bentheim Klinik für Dermatologie
    Bad Bentheim, 48455, Germany
  • Charité - Universitätsmedizin Berlin Klinik für Dermatologie, Venerologie und Allergologie Psoriasis Studien Zentrum
    Berlin, 10117, Germany
  • Rothhaar Studien GmbH Dermatologisches Studienzentrum
    Berlin, 10783, Germany
  • Hautarztpraxis Dr. Wildfeuer
    Berlin, 13055, Germany
  • Klinikum Bielefeld Klinik für Dermatologie und Allergologie
    Bielefeld, 33647, Germany
  • Hauttumorzentrum Ruhr- Universität im St. Josef Hospital
    Bochum, 44791, Germany
  • Hautarztpraxis Dr. Niesmann und Dr. Othlinghaus
    Bochum, 44793, Germany
  • Universitätsklinikum Bonn (AöR) Klinik und Poliklinik für Dermatologie und Allergologie
    Bonn, 53127, Germany
  • Elbe Klinikum Buxtehude Klinik für Dermatologie
    Buxtehude, 21614, Germany
  • Rosenpark Research
    Darmstadt, 64283, Germany
  • Universitätsklinikum Carl Gustav Carus Klinik und Poliklinik für Dermatologie
    Dresden, 01307, Germany
  • Universitätsklinikum Erlangen Hautklinik
    Erlangen, 91054, Germany
  • Universitätsklinikum Frankfurt Klinik für Dermatologie
    Frankfurt, 60590, Germany
  • Derma-Study-Center-Friedrichshafen
    Friedrichshafen, 88045, Germany
  • Gemeinschaftspraxis Rotterdam & Kollegen Facharzt für Haut & Geschlechtskrankheiten
    Gelsenkirchen, 45883, Germany
  • Universitätsklinikum Hamburg-Eppendorf, Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen
    Hamburg, 20246, Germany
  • SCIderm GmbH
    Hamburg, 20354, Germany
  • Medizinische Hochschule Hannover Klinik für Dermatologie Allergologie und Venerologie
    Hannover, 30625, Germany
  • Universitäts-Hautklinik Heidelberg
    Heidelberg, 69120, Germany
  • Klinik für Dermatologie, Venerologie und Allergologie Universitätsklinikum Schleswig-Holstein, Campus Kiel Psoriasis-Zentrum
    Kiel, 24105, Germany
  • Exellenzzentrum Entzündungsmedizin (CCIM) Universitätsklinikum Schleswig-Holstein, Campus Lübeck
    Lübeck, 23538, Germany
  • University Medical Center Mainz Department of Dermatology and Allergy, Clinical Research Center
    Mainz, 55131, Germany
  • Universitätsklinikum Mannheim der Universität Heidelberg Klinik für Dermatologie, Venerologie und Allergologie
    Mannheim, 68167, Germany
  • Technische Universität München Klinik und Poliklinik für Dermatologie und Allergologie
    München, 80802, Germany
  • Klinische Forschung Osnabrück - Klifos
    Osnabrück, 49074, Germany
  • KLINIKUM VEST GmbH Knappschaftskrankenhaus Recklinghausen Klinik für Dermatologie und Allergologie
    Recklinghausen, 45657, Germany
  • Gemeinschaftspraxis Weber & Crainic
    Schweinfurt, 97421, Germany
  • Hautarztpraxis Dres. Leitz
    Stuttgart, 70178, Germany
  • University Medical Center University of Tübingen
    Tübingen, 72076, Germany
  • Hautarztpraxis
    Witten, 58453, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Jan 2019, 14 months.

Results were first posted in Feb 2020, 1 year after primary completion.

Of 40 industry-sponsored phase 4 interventional studies under Psoriasis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 14 months is below that.

Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2017
First posted
Nov 6, 2017
StartActual
Nov 3, 2017
Primary completionActual
Jan 24, 2019
CompletionActual
Mar 21, 2019
Results first posted
Feb 10, 2020
Last update
Mar 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03331835
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
Nov 6, 2017
Start date
Nov 3, 2017
Primary completion
Jan 24, 2019
Completion
Mar 21, 2019
Results posted
Feb 10, 2020
Last update
Mar 13, 2025

Study contacts

Medical Expert
study director · LEO Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brodalumab

Start the discussion